$2.46
0.125.13%
At close: -
$2.46
0.000.00%
After Hours: 7:03 PM EDT
Comments
Loading...
Genelux Insider Trading Activity | NASDAQ:GNLX | Benzinga
Track the latest Genelux insider trading activity. Stay informed on recent buys, sells, and market impact for Genelux stock.
What is Insider Activity?
Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide valuable insights into their confidence in the company's future performance.
What are Genelux Corp Insiders Doing?
Insiders have report no purchases/sales in the last 30 days.
Notable Recent Insider Buys and Sales
There has been no Insider buying or selling in the last 90 days.
Ownership Statistics for Genelux Corp
Shares Outstanding
37.604M
Insider Shares Owned
1.229M
Insider Percentage Owned
3.27%
Institutional Shares Held
2.211M
Institutional Percentage Held
6.39%
| Dec 30, 2024 | James Tyree | — | -3.46K | $2.46 | -$8.51K | SELL | -7.03% | 45.79K | Dec 30 | View |
| Dec 18, 2024 | Thomas Zindrick | PRESIDENT AND CEO | -14.31K | $2.34 | -$33.50K | SELL | -27.70% | 37.37K | Dec 16 | View |
| Dec 18, 2024 | Lourie Zak | CHIEF FINANCIAL OFFICER | -2.10K | $2.34 | -$4.92K | SELL | -4.90% | 40.80K | Dec 16 | View |
| Dec 18, 2024 | Ralph Smalling | HEAD REGULATORY | -2.51K | $2.34 | -$5.87K | SELL | -13.33% | 16.32K | Dec 16 | View |
| Dec 18, 2024 | Joseph Cappello | VP, PHARMACEUTICAL DEVELOPMENT | -6.30K | $2.34 | -$14.74K | SELL | -30.07% | 14.65K | Dec 16 | View |
| Sep 13, 2024 | Aladar Szalay | — | -64.86K | $2.65 | -$171.68K | SELL | -5.34% | 1.15M | Sep 12 - Sep 13 | View |
| Sep 12, 2024 | James Tyree | — | -1.73K | $2.60 | -$4.50K | SELL | -3.51% | 47.52K | Sep 11 | View |
| Sep 11, 2024 | Aladar Szalay | — | -75.14K | $2.62 | -$196.61K | SELL | -5.83% | 1.21M | Sep 09 - Sep 11 | View |
| Sep 06, 2024 | Aladar Szalay | — | -42.82K | $2.09 | -$89.61K | SELL | -3.21% | 1.29M | Sep 03 | View |
| Aug 30, 2024 | Aladar Szalay | — | -265.55K | $2.09 | -$554.41K | SELL | -16.62% | 1.33M | Aug 28 - Aug 30 | View |
| Aug 27, 2024 | Aladar Szalay | — | -91.63K | $2.19 | -$200.28K | SELL | -5.42% | 1.60M | Aug 23 - Aug 27 | View |
| Jul 08, 2024 | Yong Yu | VP, CLINICAL TRIAL OPERATIONS | 8.37K | $2.12 | -$14.52K | GRANT | 334.76% | 10.87K | Feb 19 - Jun 24 | View |
| Jul 08, 2024 | Sean Ryder | GENERAL COUNSEL | 6.71K | $2.12 | -$11.65K | GRANT | 52.93% | 19.39K | Feb 19 - Jun 24 | View |
| Jul 08, 2024 | Caroline Jewett | HEAD QUALITY | -206.00 | $2.12 | -$10.52K | SELL | -1.26% | 16.17K | Feb 19 - Jun 24 | View |
| Jun 07, 2024 | James Tyree | — | 6.25K | $0.00 | $0.00 | BUY | 180.64% | 9.71K | May 29 | View |
| Jun 07, 2024 | John Smither | — | 6.25K | $0.00 | $0.00 | BUY | 90.32% | 13.17K | May 29 | View |
| Jun 07, 2024 | Thomas Zindrick J.D., Attorney-in-Fact | — | 2.50K | $0.00 | $0.00 | BUY | 0.54% | 465.96K | May 29 | View |
| Jun 07, 2024 | Mary Mirabelli | — | 8.00K | $0.00 | $0.00 | BUY | 179.37% | 12.46K | May 29 | View |
| Jun 07, 2024 | Yong Yu | VP, CLINICAL TRIAL OPERATIONS | 2.50K | $0.00 | $0.00 | BUY | ∞ | 2.50K | May 29 | View |
| Jun 07, 2024 | Thomas Zindrick | PRESIDENT AND CEO | 200.00K | $0.00 | $0.00 | BUY | 1365.09% | 214.65K | May 29 | View |
| Jun 07, 2024 | Ralph Smalling | HEAD REGULATORY | 1.25K | $0.00 | $0.00 | BUY | 10.36% | 13.31K | May 29 | View |
| Jun 07, 2024 | Sean Ryder | GENERAL COUNSEL | 10.00K | $0.00 | $0.00 | BUY | 1748.25% | 10.57K | May 29 | View |
| Jun 07, 2024 | Lourie Zak | CHIEF FINANCIAL OFFICER | 31.25K | $0.00 | $0.00 | BUY | ∞ | 31.25K | May 29 | View |
| May 15, 2024 | Aladar Szalay | — | -35.97K | $3.62 | -$130.38K | SELL | -2.08% | 1.69M | May 13 - May 15 | View |
| May 09, 2024 | Aladar Szalay | — | -19.94K | $3.78 | -$75.30K | SELL | -1.14% | 1.73M | May 07 - May 08 | View |
| May 01, 2024 | Aladar Szalay | — | -60.00K | $3.23 | -$193.93K | SELL | -3.32% | 1.75M | Apr 29 - May 01 | View |
| Apr 24, 2024 | Aladar Szalay | — | -44.40K | $3.51 | -$155.65K | SELL | -2.40% | 1.81M | Apr 22 - Apr 24 | View |
| Apr 18, 2024 | Aladar Szalay | — | -71.42K | $3.59 | -$256.23K | SELL | -3.72% | 1.85M | Apr 16 - Apr 17 | View |
| Dec 18, 2023 | Yong Yu | VP, CLINICAL TRIAL OPERATIONS | -32.53K | $13.16 | -$428.18K | SELL | -100.00% | 0.00 | Dec 15 | View |
| Dec 14, 2023 | James Tyree | DIRECTOR | -9.00K | $13.22 | -$118.97K | SELL | -72.23% | 3.46K | Dec 13 | View |
| Dec 14, 2023 | John Thomas | DIRECTOR | -9.00K | $13.38 | -$120.39K | SELL | -1.90% | 463.46K | Dec 13 | View |
| Dec 08, 2023 | Yong Yu | VP, CLINICAL TRIAL OPERATIONS | -36.80K | $11.85 | -$436.00K | SELL | -53.08% | 32.53K | Dec 07 | View |
| Nov 22, 2023 | Yong Yu | VP, CLINICAL TRIAL OPERATIONS | -18.66K | $10.26 | -$191.56K | SELL | -21.21% | 69.33K | Nov 21 | View |
| Nov 21, 2023 | Yong Yu | VP, CLINICAL TRIAL OPERATIONS | -18.14K | $11.60 | -$210.43K | SELL | -17.09% | 88.00K | Nov 17 - Nov 20 | View |
| Oct 26, 2023 | Aladar Szalay | 10% OWNER | -5.70K | $19.40 | -$110.64K | SELL | -0.30% | 1.92M | Oct 25 | View |
| Oct 25, 2023 | Aladar Szalay | 10% OWNER | -49.99K | $19.97 | -$998.37K | SELL | -2.53% | 1.93M | Oct 23 | View |
| Oct 25, 2023 | Yong Yu | VP, CLINICAL TRIAL OPERATIONS | 0.00 | $12.55 | -$68.15K | SELL-OPTIONS | 0.00% | 106.14K | Oct 24 | View |
| Oct 16, 2023 | John Thomas | DIRECTOR | -3.33K | $20.71 | -$69.04K | SELL | -0.70% | 472.46K | Oct 16 | View |
| Oct 11, 2023 | Yong Yu | VP, CLINICAL TRIAL OPERATIONS | 0.00 | $14.01 | -$83.26K | SELL-OPTIONS | 0.00% | 106.14K | Oct 10 | View |
| Oct 10, 2023 | Aladar Szalay | 10% OWNER | -14.25K | $24.93 | -$355.23K | SELL | -0.72% | 1.98M | Oct 05 | View |
| Oct 04, 2023 | Aladar Szalay | 10% OWNER | -75.69K | $25.49 | -$1.93M | SELL | -3.66% | 1.99M | Oct 03 | View |
| Sep 29, 2023 | Aladar Szalay | 10% OWNER | -13.55K | $24.41 | -$330.67K | SELL | -0.65% | 2.07M | Sep 27 - Sep 28 | View |
| Sep 27, 2023 | Aladar Szalay | 10% OWNER | -42.26K | $24.38 | -$1.03M | SELL | -1.99% | 2.08M | Sep 25 - Sep 26 | View |
| Sep 27, 2023 | Yong Yu | VP, CLINICAL TRIAL OPERATIONS | 0.00 | $14.78 | -$91.33K | SELL-OPTIONS | 0.00% | 106.14K | Sep 26 | View |
| Sep 25, 2023 | Aladar Szalay | 10% OWNER | -16.59K | $27.85 | -$462.00K | SELL | -0.78% | 2.12M | Sep 21 - Sep 22 | View |
| Sep 21, 2023 | Yong Yu | VP, CLINICAL TRIAL OPERATIONS | 0.00 | $16.98 | -$131.79K | SELL-OPTIONS | 0.00% | 106.14K | Sep 20 | View |
| Sep 21, 2023 | Sean Ryder | GENERAL COUNSEL | 0.00 | $18.00 | -$240.00K | SELL-OPTIONS | 0.00% | 572.00 | Sep 20 | View |
| Sep 20, 2023 | Aladar Szalay | 10% OWNER | -62.46K | $24.92 | -$1.56M | SELL | -3.78% | 1.59M | Sep 18 - Sep 19 | View |
| Sep 18, 2023 | Yong Yu | VP, CLINICAL TRIAL OPERATIONS | 0.00 | $13.94 | -$165.23K | SELL-OPTIONS | 0.00% | 106.14K | Sep 15 | View |
| Sep 18, 2023 | John Thomas | DIRECTOR | -6.67K | $23.45 | -$156.31K | SELL | -1.38% | 475.79K | Sep 15 - Sep 18 | View |
| Sep 15, 2023 | Yong Yu | VP, CLINICAL TRIAL OPERATIONS | -29.80K | $21.14 | -$629.93K | SELL | -21.92% | 106.14K | Sep 13 | View |
| Sep 15, 2023 | Aladar Szalay | 10% OWNER | -44.31K | $21.80 | -$965.90K | SELL | -2.65% | 1.62M | Sep 13 - Sep 14 | View |
| Sep 14, 2023 | John Smither | DIRECTOR | -900.00 | $20.78 | -$18.70K | SELL | -11.51% | 6.92K | Sep 13 | View |
| Sep 13, 2023 | Aladar Szalay | 10% OWNER | -52.62K | $22.23 | -$1.17M | SELL | -3.06% | 1.67M | Sep 11 - Sep 12 | View |
| Sep 11, 2023 | Aladar Szalay | 10% OWNER | -37.28K | $23.57 | -$878.60K | SELL | -2.12% | 1.72M | Sep 07 - Sep 08 | View |
| Aug 30, 2023 | Yong Yu | VP, CLINICAL TRIAL OPERATIONS | -19.80K | $24.70 | -$489.06K | SELL | -12.71% | 135.94K | Aug 30 | View |
| Aug 22, 2023 | Caroline Jewett | HEAD QUALITY | -515.00 | $23.73 | -$12.22K | SELL | -31.21% | 1.14K | Aug 18 | View |
| Aug 22, 2023 | Ralph Smalling | HEAD REGULATORY | -935.00 | $23.73 | -$22.19K | SELL | -31.17% | 2.06K | Aug 18 | View |
| Aug 22, 2023 | Doug Samuelson | CHIEF FINANCIAL OFFICER | -1.30K | $23.73 | -$30.78K | SELL | -36.03% | 2.30K | Aug 18 | View |
| Aug 22, 2023 | Sean Ryder | GENERAL COUNSEL | -328.00 | $23.73 | -$7.78K | SELL | -36.44% | 572.00 | Aug 18 | View |
| Aug 22, 2023 | Joseph Cappello | VP, PHARMACEUTICAL DEVELOPMENT | -3.27K | $23.73 | -$77.48K | SELL | -36.28% | 5.74K | Aug 18 | View |
| Aug 22, 2023 | Yong Yu | VP, CLINICAL TRIAL OPERATIONS | -3.27K | $23.73 | -$77.48K | SELL | -2.05% | 155.74K | Aug 18 | View |
| Aug 22, 2023 | Thomas Zindrick | PRESIDENT AND CEO | -8.35K | $23.73 | -$198.12K | SELL | -36.30% | 14.65K | Aug 18 | View |
| Jan 31, 2023 | Qian Zhang | ASSOCIATE VP, RESEARCH | 200.00 | $6.25 | $1.25K | BUY | 0.15% | 133.53K | Jan 26 | View |
FAQ
Is insider trading legal?
Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades.
What are some examples of market manipulation?
Insider trading, pump and dump schemes, front running and wash trades are all examples of market manipulation. Investors who track insider asset movement should think carefully about why these insiders are trading their stocks before moving forward.
Browse insider trades on all stocks.